Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919382 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
A Phase 2 study of Stage IV Lung Cancer AJCC v8 and Stage IVA Lung Cancer AJCC v8, sponsored by Dwight Owen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 5
- Study locations
NCT04919382 is a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Stage IVA Lung Cancer AJCC v8 that is actively recruiting participants, run by Dwight Owen. The registered enrollment target is 56 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04919382, a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Stage IVA Lung Cancer AJCC v8, is actively recruiting participants, sponsored by Dwight Owen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- DRUG Temozolomide
Study Locations (5)
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919382
The ClinicalTrials.gov registry entry for NCT04919382 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower). The listed sponsor is Dwight Owen, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04919382 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT04919382 about?
NCT04919382 is a clinical study titled "Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer". This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways ...
What is the current status of trial NCT04919382?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-01-26. Estimated completion is 2027-12-31.
What conditions does trial NCT04919382 study?
This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma.
What interventions are being tested in trial NCT04919382?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT04919382?
This trial is sponsored by Dwight Owen, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919382 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Lung Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RECRUITING · Phase 2
-
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
RECRUITING · Phase 2
-
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.